Ladies and gentlemen, good morning, and welcome to the Second Quarter 2019 Earnings Release Conference Call for FMC Corporation. Phone lines will be placed on a listen-only mode throughout the conference. After the speakers' presentation, there will be a question and answer period. As a reminder, this conference is being recorded. I will now turn the conference over to Mr. Michael Wherley, Director of Investor Relations for FMC Corporation. Mr. Wherley, you may begin.

Thank you and good morning, everyone. Welcome to FMC Corporation's second quarter earnings call. Joining me today are Pierre Rondeau, Chief Executive Officer and Chairman; Mark Douglas, President and Chief Operating Officer; and Andrew Sandifer, Executive Vice President and Chief Financial Officer. Pierre will review FMC's second quarter performance and provide the outlook for the rest of 2019. Andrew will provide an overview of select financial results, Mark will then address the long-term sustainable growth for Rynaxypyr and Cyazypyr insect controls. We will then address your questions. The slide presentation that accompanies our results, along with our earnings release and 2019 outlook statement are available on our website and the prepared remarks from today's discussion will be made available after the call. Finally, let me remind you that today's presentation and discussion will include forward-looking statements that are subject to various risks and uncertainties concerning specific factors including but not limited to those factors identified in our press release and in our filings with the SEC. Information presented represents our best judgment based on today's information. Actual results may vary based upon these risks and uncertainties. Today's discussion in this forum materials will include references to adjusted EPS, adjusted EBITDA, adjusted cash from operations and free cash flow, all of which are non-GAAP financial measures. Please note that earnings shall mean adjusted earnings and EBITDA shall mean, adjusted EBITDA for all income state references. A reconciliation and definition of these terms as well as other non-GAAP financial terms to which we may refer during today's call are provided on our website. With that, I'll now turn the call over to Pierre.

Thank you, Michael, and good morning, everyone. As you saw in our earnings release FMC continued to outperform the market as we have for the past seven quarters. We delivered results in-line with the forecast and adjusted to specific global conditions in the quarter. Turning to Slide 3. FMC reported $1.2 billion in second quarter revenue, which reflects the year-over-year increase of 4.5% on the reported basis and 9% organic growth excluding FX headwinds. This increase was mostly driven by strength in Brazil, India and EMEA. Adjusted company EBITDA was $330 million, an increase of 6% compared to recast financials from last year and $3 million above the midpoint of the guidance. Company EBITDA margins were up 28%, but year-over-year despite $64 million in combined headwinds from raw material cost and foreign currencies. Adjusted EPS was $1.66 in the quarter, an increase of 11% versus weaker Q2, 2018 and $0.01 above the midpoint of our guidance. The strong year-over-year EPS growth was driven by price increase, higher volume and the lower share count. Moving now to second quarter revenue on Slide 4. Q2 revenue grew 4.5% versus prior year, with volume contributing 5% growth and price mix to another 3% growth. This was offset partially by 4% headwind from FX. Although, Q2 is a seasonally smaller quarter of the year in Latin America, sales in that region grew 29% year-over-year or 34% organically, continuing the trend from Q1. Drivers include strong revenue growth in Brazil across the portfolio with high demand for applications on cotton and sugarcane, and price increases that more than offset the impact of FX on both revenue and earnings. Following such a strong first half in Latin America, it is important to note that we continue to monitor channel inventory levels of FMC products very closely…

Thanks Pierre. Let me start this morning with a few specific income statement items. Interest expense for the quarter was $4 million higher than implied by our prior full year guidance due to higher interest rates on foreign borrowings and higher than anticipated commercial paper balances. Interest expense for the full year is now expected to be in the range of $144 million to $148 million. The adjusted effective tax rate for the quarter was 15%. We are maintaining our full year tax rate guidance of 14% to 16%. Weighted average diluted shares outstanding for the second quarter was $132.3 million, down nearly $4 million shares versus the prior year period, reflecting the benefit of the $400 million in share repurchases, we've made over the past three quarters. Moving onto the balance sheet and cash flow. Gross debt as of June 30th was $3.2 billion, up roughly $100 million from the end of March. Gross debt to trailing 12 month EBITDA at quarter end was 2.8x. This is above our targeted leverage of 2.5x due to the seasonality of our cash flow and the timing of share repurchases. We continue to expect to see leverage drop to 2.5xor lower for the full year. Turning to Slide 9. Adjusted cash from operations was negative $174 million in the first half of 2019, below the prior year period. Non-recurring impacts that benefited working capital in the prior year period as discussed in our last earnings call remain the largest contributor to the year-on-year change. Additionally, cash from operations in the second quarter was also impacted by credit term accommodations made to certain North American customers in light of extreme market conditions, more than half of which have already been paid to us in Q3. We also had higher sales in Latin America…

Thank you, Andrew. Over the last few months, we've seen numerous published reports discussing our diamide insecticide portfolio, speculating on the timing of patent expirations and the impact these may have on the long-term profitability and growth of these important active ingredients. I want to take the time today to provide further clarity on not only our patent estate and the timing of key patent milestones, but also on other critical elements that will allow FMC to continue to profitably grow the diamide franchise well beyond the expiration of key patents. These other critical elements include registration and data protection, commercial strategies, brand recognition, as well as manufacturing and supply chain complexity. Our diamide portfolio consists of two key molecules, Rynaxypyr and Cyazypyr insect controls with current combined annual revenues of approximately $1.5 billion. It's important to note that Rynaxypyr and Cyazypyr are FMC's trademark brand names for the active ingredients chlorantraniliprole and Cyantraniliprole. These two molecules class-leading in terms of performance, combining highly effective low dose rates with fast-acting systemic long residual control. These attributes quickly established Rynaxypyr's the world's leading insect control technology and we expect it to continue a strong growth trajectory. Moving to Slide 11 to begin our discussion of the diamide patent state. Let me first pause to recognize DuPont. Out of all the quality assets we acquired in 2017, the IP estate and thought that went into building the IP protection of these molecules was extremely well done. Today I will largely confine my comments to Rynaxypyr, though the same comments are generally true for Cyazypyr with extended timelines by 18 months. The Rynaxypyr patent estate is made up of several different patent families which cover composition of matter - both the active ingredient and certain intermediates - manufacturing processes - both the active…

Thank you, Mark, for covering that important topic. To conclude our prepared remarks, FMC delivered another quarter of financial performance despite the challenging Ag environment in the U.S. Volume demand and price increases in other regions around the world are continuing to deliver strong revenue and EBITDA growth. At the beginning of this month, we successfully launched a new SAP system with the pellets in Brazil. The new system is performing very well. 20% of FMC now operates on the new S/4 HANA system and we expect to complete the full implementation in Q2 2020. The Brazil launch is a major milestone in the implementation process which is giving us strong confidence, that we will be able to implement the full system without disrupting our operations. In May, we indicated that we will provide an update on the R&D pipeline on today's call, but we felt more important to dispel misperceptions about our diamide franchise. Rather than squeeze an R&D update into a future earnings call, we will have more comprehensive and in-depth R&D investor event in the first half of this year. FMC remains well-positioned to outperform the industry and our focus on crop chemicals and biological product is an advantage. Short-term execution is delivering superior quarterly results and we are confident that our current portfolio and technology pipeline will deliver longer-term growth. I will now turn the call back to the operator for questions. Thank you for your attention.

[Operator Instructions] And we'll go to the line of Chris Parkinson with Credit Suisse. Please go ahead.

As we enter 2020, you have a few moving parts on the cost front, including a new baseline for raw materials just given on what's happening in 2019, the SAP which you mentioned, as well as the roll off of the TSA among a few others. Can you just update us on your thoughts regarding the setup for the second half and also just into 2020? Kind of run rates et cetera, your general line of sight into these variables and your conviction on your ability to drive margins higher?

Sure, Chris. As you know, we had adverse cost and a part of those costs will not be seen next year. So we know we're going to start 2020 with a tailwind from a cost-standpoint and also from an FX standpoint. There is also the fact that we are expecting to get out of the TSA with DuPont and settled by Q2 2020the new SU on a system. I look at two buckets. The total cost will be the increase in cost we are facing in 2019. We will not repeat themselves in 2020. But we will still see only a part of that coming. We have not yet quantified exactly how this will be impacting next year. We know it will be a tailwind but don't take the entire cost increase into 2020. From an S/4 HANA implementation and TSA, we still believe that the cost saving on an annual basis will be in the $60 million to $100 million a year, but we will only see fraction of that in 2020 and same thing, we have not yet quantified. So we have two source of benefits from a cost standpoint that we will eliminate a bit more time most likely at the Q3 earnings call to give you a more qualified number. The other thing which is positive as we are seeing today and we are pleased with as the cost increase - decreasing in H2 as well as FX, price is sticking quite well. So it's also a third tailwind we will see in 2020. You guys have to give us a bit more time. We're still highly focused on 2019. Those are tailwind for 2020. But we're hoping to quantify that in next two, three months.

And just on the cash generation fronts. You put some targets out there which are kind of in the stark contrast to the old FMC, but obviously in a good way. Can you just comment on your progress on the cash conversion for 2019, what else needs to be done in the second half and into 2021 to kind of further drive that conversion up to a peak level potentially let's say 85ish%. Just any incremental color on the moving parts will be greatly appreciated. Thank you.

Yes, the cash, in fact there is not much change on the cash forecast for the year versus what we were expecting the difference as Andrew said in the prepared remarks was Q2 was not as cash generative as we are hoping, because we made the commercial decision to support our customers distributors and growers in Q2 we are facing tough very challenging time and give them some a break on the cash correlation, a big part of that has been paid as was promised and will be seen in Q3 and Q4. So not much change in term of the forecast outlook for the year, maybe a bit more weighted towards Q3, Q4, then we're expecting, Andrew you want to add anything?

So I think for the current year. I think Pierre comments are spot on. I do remind everyone that in the first half of last year, we did have some benefits to working capital that don't repeat related to the DuPont transaction both on inventories and payables, as well as a pretty market step down and in past news in Brazil. So that comparison is a bit extreme. I think looking beyond 2019. I do think that long term 80%-ish conversion of free cash flow from net income. It's still very much in reach, we do need to see a step down in our legacy and transformation spending, which we anticipate as we move past the S-4 HANA implementation in the finalization of the DuPont integration. And continue to drive efficiency and working capital, but very much in reach. I think this year's the cash flow forecast as Pierre mentioned, as staying where we are and really does give us the capacity to commit to large return of capital to shareholders, both through share repurchases and the dividend and the flexibility to do some incremental investment depending on opportunities through the rest of the year.

Next we'll go to the line of Mark Connelly with Stephens Inc. Please go ahead.

Pierre every quarter we get questions about whether the diamide growth can continue. I think, in addition to the confusion over the patents. There is some misunderstanding about how FMC goes to market with products versus the way the previous owner did, so can you talk about your market penetration and why you're confident about diamide growth?

I think there is not a fundamental difference in the way we go-to-market versus the previous owner. I think we just have a very different profile in terms of the crops to which we sell and the region of the world, which we sell. So, it allows us to, to keep on penetrating markets, which we are underpenetrated in the past by DuPont's, not because there is as much of a difference of approach and usage. Just because of the fact we are a different company and we are benefiting from position in crops, which are very strong crops for Rynaxypyr and Cyazypyr. There is also the fact that as we've seen in the prepared remarks, we keep on getting registration, especially for sales appear in multiple countries and that is generating more growth. So when we look at the long term. I would not say that we would continue in the 15% to 25% growth rate of the franchise as we had last year and this year, but a long-range plan, we would be doing taking us way into the next 10 years. Looking for mid-single-digit to high single-digit growth rate for the diamide is very appropriate. Mark, do you want to add any color to this?

Yes, I think we're not finished with the sales synergies. So that's where a lot of the growth is coming from. So greater market access. Pierre said for Cyazypyr, we had - this year, we've had eight new registrations in eight different countries, both in Europe and in Africa. We continue to leverage our position with major co-ops and distributors in the South of Latin America in the U.S. and we have our new channel access in India, which is a large market for us. So wherever those niche crops are in terms of what I would consider fruit and vegetables, that's why we're seeing continued growth. So you can focus on Asia, you can focus on the south of Europe. You can focus on the South of Latin America and Mexico.

There is a final point, maybe this point is a bit different from what the previous owner deal, those all the comments made by Mark. We are looking at Rynaxypyr and Cyazypyr had a great partnering tool with other companies and as we said, we have partnership and are negotiating with about 15 companies. We are allowing those companies under some conditions to sell Rynaxypyr and Cyazypyr in different crops different part of the world. So those companies are increasing dramatically market reach and allowing us to grow faster and that is a very profitable way for us to grow the franchise, it's not at all EBITDA dilutive and it's a tool we intend to use for the years to come. I think our competitors understand well, the quality of the patent estate and are very willing to enter into those 10 years contract or more to partner with FMC on those molecules.

I want to follow up with a question about Brazil, you've obviously been exceptionally strong there and that's been a core strength of FMC for pretty much forever. We're starting to see some big retail players and distribution struggled down there and we've got a major North American retailer talking enthusiastically about that market. If we do see the Brazil ag retail market gradually shift to be more like the U.S., how is that going to affect you in Brazil and how realistic do you think it is that that happens given the massive differences in market structure down there?

So first, let me make a statement. As a large supplier of crop chemicals to the ag market, we like the U.S. structure. We do like to have large buyers, well established companies, public or private or corps, which play by the rules of the time and pay in time. So we are not adverse at all to a market outside of the U.S. starting to structure itself more like a U.S. market. It is not - it's good from a cost standpoint, it's good from a cash standpoint, it's good from an operation standpoint. Now, I still believe, if you look at the size of the growers in Brazil that we will see last distributors at our U.S. model happening, but it's going to take some time. It's a very big market, it's a market where there is a large number of large players, who are growers. Soto see a market where you go down to five or six or seven largest distributors like we have in U.S., I don't see that in the foreseeable future. Nevertheless, a transition more towards the U.S. market is not a negative for us. Mark?

Yes, only thing I would add to that is you've got some extremely large co-ops in the South of Brazil, which operate in a very similar way to the U.S. model in terms of scale and breadth of capabilities. So I think in parts of Brazil, you already have more of a U.S. type model. I do think the market is consolidating in terms of distribution, you are seeing acquisitions and roll ups. I think that will continue. But as Pierre said, I think it will take some time to get to where we are in the U.S. for instance. But I do see it going in that direction.

And we don't see that as a negative at all.

No, not at all.

And next we go to line of Frank Mitsch with Fermium Research. Please go ahead.

Mark, appreciate the review of Rynaxypyr and Cyazypyr patent protection time on that. Obviously, you mentioned that's $1.5 billion in terms of sales today, so very attractive. I just wanted to drill into one of the comments you made, that it would be very capital intensive for someone else to duplicate your supply chain. Can you give us an order of magnitude of what would be involved there in terms of dollars and cents?

It's complex to do, because understand that when you have a process which is 16 steps, which for us is done through a series of partners who are manufacturing some of the intermediates and some of the final steps, which are made by us, it is a very-very complex network. You would not imagine somebody building that in a short period of time over a single site. So it would require not only capital spending at the level of the company itself, which intend to, but most likely to find partners to produce some of those intermediates. None of these partners could be the partners we do have today, who are in exclusive arrangements with our sales for the long-term. The number is certainly, we have not quantified if somebody would try to replicate all or part of a product. But, I'd say, for part of the total, to see numbers more in the $1 billion range would not be surprising.

Pierre, I believe you mentioned that at this point, here we sit on July 31st, you have 70% of orders already received to meet your second-half objectives. I'm just curious, how does that stand in prior years in terms of the percent of orders that you would already have in-house? Is that somewhat typical or is that a higher than normal sort of percentages?

It is the same as last year, which was a very strong year. So I would say the last two years, we reached that 70% number. Usually by this time of the year, we are about 40% to 50%, maybe 40% range at this time of the year. Last year for the first time, we hit the 70% range, which was positive and resulted into a very strong second half. And once again this year, we are at the same place. So we view that as a positive versus a normalized year.

We do have a question from the line of P.J. Juvekar with Citi. Your line is open.

Given the delayed planting inventories in the channel, question on that, if I look at your inventories, they are up year-over-year, so, like, compared to second quarter of last year. So was there any missed early application that led to inventory increase? And where do we stand about inventories? The reason I'm asking is, couple of years ago we had this inventory situation in Brazil. That was painful and took some long time to get that inventories down. So how do you compare that situation?

Sure. So first of all, let me make a comment outside of North America. We are in low to normal level of inventories. So we currently have a situation in Brazil. Actually, we have a new process in place, as we said before. I think it's the lowest ever level of inventory in the channel we are having. In other part of the world, we are under a more normal situation. We recognize that there was misapplication in North America. We are taking that into account in our forecast for the rest of the year where we have made plans which are contemplating not selling some product, which will already be in inventory and our customers or in the channel, or we have also accounted for returns. So that's a place where we are facing fundamental difference from Brazil in 2015. Brazil in 2015 was a consequence of a process from all of the ag players over multiple years. We had multiple years of selling too much into the channel. Here it's a more isolated event over this year, because of weather conditions. So we have a year which is difficult versus multiple years in 2015 where the channel was too loaded. So it is not good, but it is manageable, accounted for in our forecast. But we are still watching it. Mark, you want to say?

Yes, PJ, the only nuance I would put to what Pierre said about the U.S. is, the U.S. for us is really two core markets, what we call the Heartland's, which is the Midwest, mainly row crop business. And then the Horseshoe, which stretches all the way from California through the Southern states up the East Coast, very different situation in those two markets. I would say, where we know we have or we think we have higher channel inventories, is in the Heartland on the row crops where we believe pre-emergent herbicides were missed in certain areas. But in the rest of the U.S., where all the niche crops are grown, we're in absolutely normal conditions. So it's very-very isolated to that part of the U.S. and that part of the business.

And a quick one for Andrew. Andrew, you mentioned the extended terms of payments in the U.S. for growers; can you talk about when did we do that last time and what was your experience back then?

Yes, we've done it on a very limited basis in the past. Our experience has always been that we catch right back up as agreed. Yes, I think, as I mentioned, over half the accommodations we gave in Q2 have already been paid at this point in Q3, and the rest will be cleared out by year-end. So really just trying to support our customers as they work through their quarter end, and what's been a tough year. But historically, in this year, I think no concerns about the collection time and timing our ability on that.

And just a quick comment, PJ. I mean, we made that decision, it is not something we've done in the past or we used to do, it was just exceptional to the - especially in the Midwest, our customers were facing a situation where we felt we had to support them. Lots of them, as we said, are big corporations. They live by their word. They pay when they say they will repay and as Andrew say, as half of it has already been done with a very precise schedule. So, no concern. It's an exceptional situation, but no concern on this.

Next we move on to the line of Vincent Andrews with Morgan Stanley. Please go ahead.

A question on the CapEx potential expansion diamide, just wondering, is that decision a function of, sort of, your assessment of how much incremental inventory you want to have for your own needs or is it a function of, perhaps as you referenced in the patent discussion, maybe extending some of the license agreements or creating new license agreements with other interested parties or is it bit of both? And is this a significant capital expenditure? What time period would it be over and potentially where would it be located?

The CapEx increase, we are, looking at today are simply due to the fact that when we made our capital, three-year capital spend plan when we acquired the DuPont business. As you remember, we were forecasting a high single-digit growth rates for those products. We've been in the 15% to 25% range since the acquisition. So we are getting tight on capacity. Those are not big capacity it's for part of the chain of manufacturing well, we're doing it. Especially, including some of the, the intermediate you’re talking about of tens of millions of dollars you're not talking hundreds of millions of dollars, for the one which are taking place potentially this year. And as we said before, from a location standpoint we have a couple of locations, but as we said before, the idea for us is to manufacture you as much as we can today outside of China. So those expansions will take place outside of China. It's not huge, but it's necessary to ensure we can keep on growing at the speed at which we are growing.

And if I could just follow up there's been a lot written recently about armyworm infestation in new geographies. I would assume that is an attractive opportunity for your diamides’ portfolio. So is that something you've already contemplated sort of as we think about your long-term growth rate or would that be incremental?

Yes, it definitely is you know the diamides are right at the top of the tree when it comes to impacting for armyworm. We've seen the growth of these pests in India. We seen it in China and it's now moving through Southeast Asia, Vietnam, Thailand moving south. So we already have in our forecast, some incremental revenue from Rynaxypyr essentially - in those countries, but we believe there is more upside as this pest becomes more prevalent especially throughout the rest of South Asia.

[Operator Instructions] We'll go to line of Joel Jackson with BMO Capital Markets. Please go ahead.

All right downgrade to one question. Thanks guys I'm just kidding. Okay, so you've got it down, the market growth to about flat. So on rough math to me that will be like a $100 million or $200 million gear, excuse me $120 million of headwinds on the topline macro pressures. You've maintained your guidance like you said despite that, could you talk about what's offsetting some of that pressure down on the macro? Thanks.

Yes, you know, I think the pressure down in the market is mostly driven by North America as we said. So what does it do to us, if you look at the disproportionate strength of our business versus many competitors outside of North America plus the fact that within North America. We do have a very balanced crop profile with loss of specialty crops. The slowdown of the world growth in Ag is impacting us not as much as it could impact other competitors. So yes, it is a bit of a headwind, but what, we are very well positioned to compensate that other by growing more into specialty crops in North America or by using the strength of our business in place like Brazil, Latin America or India. Remember, as we said, we only do 25% of our business in North America. So all in all, it is balancing out quite well for us.

Next, we go to the line of Don Carson with Susquehanna Financial. Please go ahead.

Yes, Mark a question for you on these commercial arrangements you're negotiating with other parties you say you out of the 50 now. What is the margin profitability on that and then as you bifurcate that into supplying generic AI's post patent what's the margin implications for that versus selling it on branded product?

So Don, we don't obviously give out the margin expectations. But what I put in my prepared remarks were the fact that when we have these agreements and we make these sales. They're not EBITDA dilutive to our overall business so when you think about it there are highly profitable marketing-exercise for us. Now on a pricing standpoint again, I'm not going to disclose the types of conditions we have in these various contracts, but they are very long-term in nature. And obviously the prices that we agreed with outside parties allow them to make a more than adequate margin on their sales. So both parties are compensated for what we're doing in the marketplace. So the bottom line is, these are highly attractive relationships for us and doubt that party partners and they are there for the long term.

Let me quantify a bit by using information, we've already shared with you. As you know, we do have depending upon the quarters and EBITDA margin for this business in the 27%, 28%. This EBITDA margin of course is driven and we've said that when we made the acquisition of DuPont with the damage which are expected to be north of 30% from an EBITDA margin. That's what we are able, through this process to protect. So we are selling this product, the active part to a partner and it's generating for us with limited SG&A spending and R&D and formulation spending an EBITDA margin north of 30%.

Next, we go to the line of Laurence Alexander with Jefferies. Please go ahead.

Just one last one on the diamide discussion, as you've looked at the manufacturing chain that already exists for these products and FMC's historical approach to re-engineering the chain and finding new manufacturing partners. How should we think about the five to 10 year opportunity for bringing down the cost of manufacturing and should we see that in terms of lower market prices. So basically protecting the growth rate and protecting the margins, which we see it as margin expansion over time?

Yes Lawrence, I mean we have our whole engineering group looking at the diamide manufacturing processes and looking at how we can bring cost down over the mid to long-term. So, that's certainly something that we're not going to let pass. We know how to do this we've done it very successfully - not only our own molecules, but other molecules as well. I wouldn't comment on this point about price volume relationships in the marketplace going longer term. In today's world, these molecules are highly valued. They produce tremendous results for their cost in use. So right now, we're growing the market at the right margin at the right price. I don't see that changing in the near term at all. So whatever we get in terms of manufacturing cost reductions over the mid-term will stay within FMC.

And we've already done in two years, in two years we've already done multiple debottlenecking, brought new partners into the process. So we already actively increasing capacity at very low cost you've not seen a major increase so far in capital spending despite the fact that we've already increased our capacity in a significant way for diamide. So your point is correct for both Cyazypyr and Rynaxypyr. We are doing it and intend to continue to do it.

And our last question is from the line of Kevin McCarthy with Vertical Research. Please go ahead.

Thanks for squeezing me in a two-part question on your capital budget. The first part is that you affirmed your range for the year at 140 to 160 yet you spent only $34 million in the first half. Looks like the last couple of years the spend has been quite back end loaded. So I was wondering if you could speak to what is driving that kind of quarterly cadence, number one. And then number two, do you have any preliminary thoughts on how the budget could trend in 2020 versus 2019?

So from a capital spending, I have been doing that for years now and I think it's been the same thing, year after year, which mean usually you start your big project, lots of your big projects are starting with - the beginning of the year, when you start with the new capital spending. So you usually highly process where there is a lot of planning an engineering study which do not represent a lot of spending. And then it accelerates by the middle of the year when things are already put in place and you start to spend the cash. So I don't think there is anything abnormal, I must say that 70% or 80% of my years in the industry yeah I have always seen back-end loaded, big engineering product and capital expenditure. I think from next year today, we have not been yet through the process. We believe we’ll have a higher capital spend, mostly due to capacity increase for the product we are commercializing new products for the existing product as the diamide.

Yes Kevin, the only thing - the attitude to what Pierre said is, basically we have two new active ingredients that are coming out of our pipeline that come to market in 2021. We're putting steel in the ground next year for that capacity expansion. So it's a combination of both current products and new pipeline products.

So you will see a slightly limited number next year for capital spend.

That's all the time that we have for the call today. Thank you and have a good day.

Ladies and gentlemen, this does conclude the FMC Corporation Conference Call. Thank you for your participation, you may now disconnect.